Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953778 · ClinicalTrials.gov registry record · NA
The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome
A NA study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- NA
- Development phase
- 24,060
- Enrollment target
NCT06953778: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT06953778 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 24,060 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06953778, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 24,060 participants
- Enrollment target
Study Summary
* The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure. * Atrial fibrillation is a common heart condition in which one of the heart chambers doesn't follow a normal rhythm. Blood clots can form as a result, and they can travel to the brain and cause strokes, or to other organs. * Almost everyone with atrial fibrillation is treated with drugs called anticoagulants ("blood thinners") to reduce the risk of stroke. These drugs also increase the risk of bleeding. * Testing for atrial fibrillation is usually done for patients who have symptoms of an irregular or unusually fast or slow heartbeat, often called "palpitations" or a sensation of the heart pounding or stopping for a short period of time. * What is not known is whether screening people who do not have symptoms of atrial fibrillation, but who are at above-average risk of getting atrial fibrillation, will reduce death, hospitalization for stroke, blood clots, heart failure more than it increases hospitalization for severe bleeding. * People who participate in the trial who are selected by chance to receive screening will wear a small heart-rate monitor (Zio Patch) on their skin for 14 days and then return it to the manufacturer. Their doctors will be notified about the results and will make decisions about any treatment to recommend. * The screening trial is expected to enroll about 24,000 VA patients nationwide and to last 7 years, but each person's active participation in the trial is completed after sending in the Zio Patch. After that, the study team will just collect information from the participant's electronic medical records.
Interventions
- DEVICE Zio XT® Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,060 participants |
| Start Date | 2027-03-08 |
| Est. Completion | 2033-10-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953778
The ClinicalTrials.gov registry entry for NCT06953778 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 24,060 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zio XT® Patch is the first listed.
NCT06953778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06953778 about?
NCT06953778 is a clinical study titled "The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome". * The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure. * Atrial...
What is the current status of trial NCT06953778?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 24,060 participants. The study started on 2027-03-08. Estimated completion is 2033-10-03.
What interventions are being tested in trial NCT06953778?
The interventions under investigation include: Zio XT® Patch (DEVICE).
Who is sponsoring clinical trial NCT06953778?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.